1. AstraZeneca plc: Company Analysis
Report Details:
Published:September 2012
No. of Pages: 35
Price: Single User License – US$5700
This analysis examines the historical and forecast performance for AstraZeneca in the prescription
pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline
analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
•Gain insight into AstraZeneca's strategic outlook across the next 6 years
•Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule
type and source
Highlights
Strategic insight into the prospects for AstraZeneca over the next six years. Picking out key
strengths, weaknesses, opportunities and threats and evaluating the company's prescription
pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
•Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical
sector
•Analyse AstraZeneca's high level of anticipated exposure to flagship product patent expiries and
the impact on company strategy
Get your copy of this report @
http://www.reportsnreports.com/reports/195545-astrazeneca-plc-company-analysis.html
Major points covered in Table of Contents of this report include
Table Of Contents
SCOPE OF ASTRAZENECA ANALYSIS
PharmaVitae Explorer database
Analysis structure
Executive summary
Strategic insight

2. Company overview
Operating performance analysis
Data sourcing
Sales data
Analyst consensus
EXECUTIVE SUMMARY
Key findings
AstraZeneca prescription pharmaceutical sales outlook
AstraZeneca’s financial outlook
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
STRATEGIC INSIGHT
Key findings
Launch/core/expiry analysis
Strategic Insight
Introduction
Re-organization of R&D operations is spurred by challenging times
Endo portfolio to see fastest sales growth thanks to lucrative diabetes partnership with Bristol-
Myers Squibb
Growth in emerging markets will partially offset generic exposure in the US and EU
CORPORATE STRUCTURE
Key findings
Background
Corporate structure
M&A history
M&A strategy
OPERATING PERFORMANCE ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported
total sales, 2005–11
Operating costs and profit analysis
Operating costs and profit analysis, 2005–11
Operating cost ratio and profit margin analysis, 2005–11
Operating cost ratio and profit margin analysis, 2011–17
Operating costs and profit analysis, 2011–17

3. APPENDIX
References
Exchange rates
List Of Tables
Table: Datamonitor’s established pharmaceutical company coverage, 2012
Table: AstraZeneca – key product overview ($m), 2011–17
Table: AstraZeneca’s financial performance ($m), 2011–17
Table: AstraZeneca launch, core and expiry portfolio overview ($m), 2011–17
Table: AstraZeneca key merger and acquisition deals, 2006–12
Table: Total AstraZeneca sales by business unit ($m), 2005–11
Table: AstraZeneca operating revenue/cost analysis ($m), 2005–11
Table: AstraZeneca operating cost ratio analysis (% of total revenues), 2005–11
Table: AstraZeneca operating cost ratio analysis (% of total revenues), 2011–17
Table: AstraZeneca operating revenue/cost analysis ($m), 2011–17
Table: Exchange rates, 2012
List Of Figures
Figure: The PharmaVitae Explorer
Figure: AstraZeneca’s prescription pharmaceutical performance, sales ($m) and growth rate (%),
2005–17
Figure: AstraZeneca’s financial performance ($m), 2005–17
Figure: AstraZeneca launch/core/expiry configuration ($m), 2011–17
Figure: AstraZeneca’s restructuring of its therapy area focus, 2012
Figure: AstraZeneca’s prescription pharmaceutical sales, by therapy area ($m), 2005–17
Figure: Enhancement of the AstraZeneca/Bristol-Myers Squibb diabetes alliance
Figure: AstraZeneca’s prescription pharmaceutical sales, by geographic region (%), 2005–17
Figure: AstraZeneca operating revenue/cost analysis ($m), 2005–17
Contact: sales@reportsandreports.com for more information.